Supernus Pharmaceuticals, Inc. (SUPN) Stock Price & Analysis
Supernus Pharmaceuticals, Inc. (SUPN) closed at USD 39.57 on Thursday, October 15, 2026, down 1.52% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 40.18; the Oct 15, 2026 session ranged USD 39.36–41.31 on volume of 911,518 shares. Market capitalization is $2.30B, with a 52-week range of USD 39.36–59.68 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SUPN.md
Key facts (SUPN)
- Last four reported quarters (through Jun 30, 2026): revenue $830M, net income -$110M (-13.2% margin), free cash flow $18.8M (SEC filings).
- 1 of 80 tracked superinvestors hold SUPN (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 2.25 on a 1–5 scale) (4 analysts), mean target USD 60.5 (range 55–67).
- Total return with dividends: 1Y -20.5% vs S&P 500 +18.1%; 5Y +25.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-03, EPS estimate USD 0.56, revenue estimate $221M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SUPN)
| USD | FY2021 | FY2022 | FY2024 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $580M | $667M | $608M | $662M | $719M | $830M |
| Gross profit | — | $580M | $524M | $584M | $644M | — |
| Operating income | $86.0M | $46.1M | -$5.3M | $81.7M | -$62.3M | -$130M |
| Net income | $53.4M | $60.7M | $1.3M | $73.9M | -$38.5M | -$110M |
| EPS (diluted) | $0.98 | $1.04 | $0.02 | $1.32 | -$0.68 | — |
| Free cash flow | — | $116M | $111M | $171M | $46.0M | $18.8M |
| Gross margin | — | 86.9% | 86.2% | 88.2% | 89.6% | — |
| Operating margin | 14.8% | 6.9% | -0.9% | 12.3% | -8.7% | -15.7% |
| Net margin | 9.2% | 9.1% | 0.2% | 11.2% | -5.4% | -13.2% |
| Revenue growth | +11.4% | +15.1% | -8.9% | +8.9% | +8.6% | — |
| Cash + short-term investments | $340M | $461M | — | — | $128M | — |
| Total debt | $379M | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SUPN)
P/S 2.8x · P/FCF 122.6x · P/B 2.2x · FCF yield 0.82% · Earnings yield -4.77%
P/E at fiscal year-ends: Dec 2024 27.4x, Dec 2023 1220.6x.
Superinvestors (SEC 13F-HR, Q2 2026) (SUPN)
1 of 80 tracked investors hold SUPN. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Third Avenue Management | 1.14% | $7.1M | Unchanged |
Analysts (SUPN)
Consensus Buy (mean 2.25 on a 1–5 scale), 4 analysts; mean target USD 60.5 (low 55, high 67).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-09 | Cantor Fitzgerald | Target raised | Overweight | $63 → $67 |
Total return (dividends reinvested) (SUPN)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -20.5% | +25.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -20.5% | +4.5% |
| Volatility (annualized) | 37.1% | 31.5% |
| Max drawdown | -30.6% (Nov 2025→Oct 2026) | -43.4% (Jan 2023→Oct 2023) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 39.57 |
|---|---|
| Change | ▼ 1.52% (down) |
| Previous Close | USD 40.18 |
| Open | USD 40.21 |
| Day Range | USD 39.36 – 41.31 |
| 52-Week Range | USD 39.36 – 59.68 |
| Volume | 911,518 shares |
| Market Cap | $2.30B |
| Exchange | NGM |
Technical Analysis (SUPN)
Nexqual's technical model rates SUPN "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.6 (neutral) |
| vs SMA50 | Below (USD 44.01) |
| MACD | -0.74 (negative) |
Analyst Ratings (SUPN)
Wall Street analysts rate SUPN "Buy" based on 4 analysts, with a mean price target of USD 60.5 (range USD 55–67), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 60.5 |
| High Target | USD 67 |
| Low Target | USD 55 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (SUPN)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.56 |
| Revenue Estimate | $221.06M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.53 vs est 0.51 ▲ beat |
| 2026-03-31 | USD 0.21 vs est 0.28 ▼ miss |
| 2025-12-31 | USD 0.88 vs est 0.28 ▲ beat |
| 2025-09-30 | USD 0.61 vs est 0.82 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (SUPN)
| Total Revenue | $830.44M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +32.40% |
| Gross Margin | +72.89% |
| Operating Margin | -2.48% |
| Profit Margin | -13.23% |
| ROE | -10.49% |
| Debt / Equity | 0.04 |
| Current Ratio | 2.08 |
| Total Cash | $372.07M |
| Total Debt | $40.17M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | $45.99M (6.4% of revenue) |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (SUPN)
Nexqual rates Supernus Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 73%, operating -2% |
| Balance Sheet | Strong — $372M cash vs $40M debt, net cash position |
| Cash Flow | Solid — FCF $46M (FY ended Dec 2025, 10-K), 6% margin |
| Efficiency | Critical — ROE -10%, ROA 0.4% |
Ownership (SUPN)
| Insider Ownership | +4.32% |
|---|---|
| Institutional Ownership | +106.11% |
| Shares Outstanding | 58.22M |
| Float | 51.74M |
| Short % of Float | +10.51% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (SUPN)
Supernus Pharmaceuticals, Inc. is led by Jack A. Khattar (age 64), Founder, President, CEO, Secretary & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Founder, President, CEO, Secretary & Director | Jack A. Khattar (age 64) |
|---|---|
| Senior VP & CFO | Timothy C. Dec (age 66) |
| Chief Scientific Officer & Senior VP of Intellectual Property | Padmanabh P. Bhatt (age 68) |
| Senior VP & Chief Technology Operations Officer | Frank Mottola (age 53) |
| Senior Vice President of Sales | Taylor Raiford |
Major Backers & Investors (SUPN)
Notable institutional backers of Supernus Pharmaceuticals, Inc. include Millennium Management, Armistice Capital, LLC, Nomura Asset Management International Inc, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Millennium Management | 6.62% |
| Armistice Capital, LLC | 4.54% |
| Nomura Asset Management International Inc | 4.08% |
| Stephens Investment Management Group LLC | 2.55% |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.45% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 24.61% |
| Vanguard Group | 19.19% |
| State Street | 5.16% |
| Dimensional Fund Advisors | 3.57% |
| Geode Capital | 2.7% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HCM | HUTCHMED (China) Limited | USD 13.94 | ▲ 3.26% |
| LQDA | Liquidia Corporation | USD 34.78 | ▲ 29.73% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.65 | ▲ 2.98% |
| RGC | Regencell Bioscience Holdings L | USD 9.52 | ▲ 16.24% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 33.62 | ▼ 5.08% |
| KNSA | Kiniksa Pharmaceuticals Interna | USD 79.94 | ▲ 1.8% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt